What's Happening?
Precigen Inc. has been granted orphan drug exclusivity by the FDA for PAPZIMEOS, its treatment for recurrent respiratory papillomatosis (RRP), a rare respiratory disease. This exclusivity prevents the approval of similar drugs for seven years, extending
PAPZIMEOS' market exclusivity through August 2032. PAPZIMEOS, developed using Precigen's AdenoVerse platform, uses a modified adenovirus to target proteins in HPV 6 and HPV 11, reducing the need for surgeries in RRP patients. The drug is commercially available in the U.S. and has shown promising long-term results, with 83% of complete responders maintaining their response for at least 36 months without additional treatment.
Why It's Important?
The orphan drug exclusivity for PAPZIMEOS strengthens Precigen's market position by providing a competitive edge and ensuring long-term revenue potential. This regulatory milestone supports the company's continued innovation in rare diseases, offering a new therapeutic option for RRP patients who typically undergo multiple surgeries annually. The promising long-term data further reinforces PAPZIMEOS as a potential new standard of care, reducing the surgical burden on patients and improving their quality of life. The exclusivity also highlights the importance of developing treatments for rare diseases, which often lack effective therapeutic options.
What's Next?
Precigen will continue to market PAPZIMEOS across the U.S., focusing on expanding its reach to major medical centers and community practices. The company may also explore additional indications for its AdenoVerse platform, leveraging its expertise in precision medicines. Ongoing follow-up studies will provide further insights into the long-term efficacy and safety of PAPZIMEOS, potentially supporting its use in broader patient populations. Precigen's efforts to secure additional regulatory approvals and expand its product portfolio could enhance its leadership in the rare disease sector.
